Here, we revealed that CDK4/6 depletion or inhibition by abemaciclib significantly inhibited CRC cell proliferation, cell cycle progression, CSC self‐renewal, and chemoresistance both in vitro and in vivo in a YAP1‐dependent manner (Figures 1 and S1). This evidence concerns the gene CDK4 and colorectal carcinoma.